selicrelumab: Clinical Trials

10 completed, 2 terminated, 1 recruiting. 12 Phase 1, 3 Phase 2, 1 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 1	12	Completed 9, Terminated 2, Recruiting 1
Phase 2	3	Completed 1, Recruiting 1, Terminated 1
Early Phase 1	1	Completed 1

Follow selicrelumab: new trials by email Literature Review of selicrelumab trials Research Report on selicrelumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma Selicrelumab, Atezolizumab - Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma	Phase 1	Terminated	The Lymphoma Academic Research Organisation	4	2019-07-04	2021-07-26
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) Regorafenib, Atezolizumab, Imprime PGG - Colorectal Cancer	Phase 1 / Phase 2	Terminated	Hoffmann-La Roche	96	2018-09-27	2023-11-07
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer Capecitabine, Atezolizumab, Ipatasertib - Metastatic Breast Cancer	Phase 1 / Phase 2	Recruiting	Hoffmann-La Roche	1132	2018-03-30	2026-11-06
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Nab-Paclitaxel, Gemcitabine, Oxaliplatin - Pancreatic Adenocarcinoma	Phase 1 / Phase 2	Completed	Hoffmann-La Roche	341	2017-07-05	2025-11-21
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Emactuzumab, RO7009789 - Neoplasms	Phase 1	Completed	Hoffmann-La Roche	38	2016-05-09	2018-05-22
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors Selicrelumab, Vanucizumab, Bevacizumab - Advanced/Metastatic Solid Tumors	Phase 1	Completed	Hoffmann-La Roche	94	2016-01-25	2020-04-07
A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors Atezolizumab, Selicrelumab - Solid Tumors	Phase 1	Completed	Hoffmann-La Roche	140	2014-12-12	2019-12-13
Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma Gemcitabine, CP-870,893 - Adenocarcinoma Pancreas	Phase 1	Completed	Abramson Cancer Center at Penn Medicine	10	2012-04-01	2018-08-27
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma CD40 agonist monoclonal antibody CP-870,893, tremelimumab, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma	Phase 1	Completed	Abramson Cancer Center at Penn Medicine	25	2010-02-01	2020-04-07
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 CP 870,893, Peptides, Oncovir poly IC:LC - Melanoma	Phase 1	Completed	H. Lee Moffitt Cancer Center and Research Institute	22	2009-10-01	2015-09-24
Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors Paclitaxel + Carboplatin + CP-870,893 - Neoplasms	Phase 1	Completed	Hoffmann-La Roche	34	2007-11-01	2017-03-27
Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors CP-870,893 - Solid Tumors	Early Phase 1	Completed	Abramson Cancer Center at Penn Medicine	10	2005-07-01	2018-08-17
Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors CP-870,893 - Advanced Solid Tumors	Phase 1	Completed	Abramson Cancer Center at Penn Medicine		2004-01-01	2018-08-28

Conditions studied

Melanoma (2)  ·  Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Lymphoma, B-Cell (1)  ·  Recurrence (1)

Sponsors

Hoffmann-La Roche (7)  ·  Abramson Cancer Center at Penn Medicine (4)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  The Lymphoma Academic Research Organisation (1)

Countries

United States (12)  ·  France (5)  ·  Spain (4)  ·  South Korea (3)  ·  Australia (2)  ·  Belgium (2)  ·  Canada (2)  ·  Denmark (2)  ·  Germany (2)  ·  Netherlands (2)  ·  Israel (1)  ·  Italy (1)  ·  Japan (1)  ·  Switzerland (1)  ·  Taiwan (1)

Top investigators

Robert Vonderheide, MD (2)  ·  Robert Vonderheide, MD, DPhil (2)  ·  Jeffrey Weber, M.D., Ph.D. (1)

Results publications

PMID 22969103, PMID 23483678, PMID 33097612, PMID 36940261, PMID 39707623, PMID 40318595

NIH funding

2015 (2), 2017 (2), 2014 (1), 2016 (1), 2023 (1)